BioCentury
ARTICLE | Emerging Company Profile

Orum’s forum

How Orum is delivering antibodies into cells

January 4, 2017 5:56 PM UTC

A major downside of therapeutic antibodies is that they can’t touch intracellular targets: the biologics are too large to diffuse across cell membranes on their own, and those entering cells via endocytosis degrade before reaching the cytosol. Orum Therapeutics Inc.’s cell-penetrating antibody platform helps the biologics escape intracellular degradation to inhibit KRAS and other cytosolic proteins that are hard to target with small molecules.

According to CEO Sung Joo Lee, the platform is designed to get antibodies into cells via endocytosis, but get them out of endosomes before they are flagged for lysosomal degradation. Lee is Orum’s founder, and until August was head of research, Asia Pacific R&D at Sanofi...

BCIQ Company Profiles

Orum Therapeutics Inc.

BCIQ Target Profiles

K-Ras (KRAS)